NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational potential of CagriSema ...

CagriSema delivers significant weight loss: In the REDEFINE 1 trial, Novo Nordisk’s CagriSema achieved a 22.7% mean weight reduction in adults with obesity or overweight without diabetes. Over half ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. About the REDEFINE clinical trial programme ...

CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with ...

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss ...